Oral administration of lipopolysaccharide exacerbates collagen-induced arthritis in mice.
We investigated whether oral administration of LPS exacerbated collagen-induced arthritis (CIA) in mice, which was an experimental model of autoimmune disease. CIA was induced by s.c. injection of type II collagen emulsified with CFA into the base of the tail (day 0) followed by a booster injection on day 21. To examine the ability of LPS to exacerbate CIA, varying doses of LPS were orally administered on day 50. The results showed that administration of LPS was followed by reactivation of CIA in a dose-related fashion. Histologically, on day 55 there were marked edema of synovium proliferated by day 50, new formation of fibrin, and intense infiltration of neutrophils accompanied with a large number of mononuclear cells. Severe destruction of cartilage and subchondral bone was also observed on day 70. The reactivation of CIA by oral administration of LPS was associated with increase in anti-type II collagen IgG and IgG2a Abs as well as varying kinds of cytokines including IL-12, IFN-gamma, IL-1beta, and TNF-alpha. Polymyxin B sulfate given either orally or i.v. suppressed the recurrence of CIA. Increased amounts of LPS were found in sera of mice given the endotoxin orally. LPS from Salmonella enteritidis, Salmonella typhimurium, and Klebsiella pneumoniae and its component, lipid A from Escherichia coli, also reactivated the disease. These findings suggest that LPS from intestinal bacteria may play a role in the exacerbation of autoimmune joint inflammation.
Yoshino
S
S
Department of Microbiology, Saga Medical School, Japan. yoshins@post.saga-med.ac.jp
Sasatomi
E
E
Mori
Y
Y
Sagai
M
M
D000284:Administration, Oral; D000818:Animals; D001169:Arthritis, Experimental / Q000209:etiology / Q000276:immunology* / Q000473:pathology* / Q000517:prevention & control; D002358:Cartilage, Articular / Q000473:pathology; D003094:Collagen / Q000276:immunology; D016207:Cytokines / Q000378:metabolism; D007074:Immunoglobulin G / Q000096:biosynthesis; D007275:Injections, Intravenous; D007711:Klebsiella pneumoniae / Q000276:immunology; D008050:Lipid A / Q000008:administration & dosage / Q000009:adverse effects; D008070:Lipopolysaccharides / Q000008:administration & dosage* / Q000009:adverse effects* / Q000037:antagonists & inhibitors / Q000097:blood; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D011112:Polymyxin B / Q000008:administration & dosage; D012477:Salmonella enteritidis / Q000276:immunology; D012486:Salmonella typhimurium / Q000276:immunology; D013583:Synovial Membrane / Q000473:pathology; D013997:Time Factors
D016207:Cytokines; D007074:Immunoglobulin G; D008050:Lipid A; D008070:Lipopolysaccharides; D003094:Collagen; D011112:Polymyxin B